ACIP recommends third MMR dose during mumps outbreaks

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The Advisory Committee on Immunization Practices (ACIP) has released an updated guidance recommending a third measles, mumps, rubella (MMR) vaccine dose for persons (previously vaccinated with 2 doses) with increased mumps risk during an outbreak.
  • Although current recommendations for 2 doses suffice for the general population, waning immunity coupled with high-intensity exposure may be insufficient to prevent mumps; these individuals are now considered to be a public health priority for preventing severe disease/complications.

Why this matters

  • Clinicians are encouraged to follow public health guidance for identifying at-risk individuals/groups during mumps outbreaks.
  • Contraindications/precautions are the same as those for routine 1-2 doses.
  • During outbreaks, persons at increased risk who have not received 2 MMR doses or have unknown vaccination status should receive 1 dose.

Key points

  • In recent years, mumps outbreaks have occurred in populations in institutional settings with close contact or close-knit communities.
  • Even where 2-dose MMR coverage is high, it has been insufficient to prevent outbreaks in prolonged, close-contact environments; waning protection after the second dose contributes to higher risk in these settings.
  • Benefit of adding a third dose outweighs risk for adverse events (AEs), which have reportedly been low and nonserious.
  • AEs should be reported to the Vaccine Adverse Event Reporting System.